1. Home
  2. FLGT vs GERN Comparison

FLGT vs GERN Comparison

Compare FLGT & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLGT
  • GERN
  • Stock Information
  • Founded
  • FLGT 2011
  • GERN 1990
  • Country
  • FLGT United States
  • GERN United States
  • Employees
  • FLGT N/A
  • GERN N/A
  • Industry
  • FLGT Medical Specialities
  • GERN Biotechnology: Pharmaceutical Preparations
  • Sector
  • FLGT Health Care
  • GERN Health Care
  • Exchange
  • FLGT Nasdaq
  • GERN Nasdaq
  • Market Cap
  • FLGT 697.3M
  • GERN 740.5M
  • IPO Year
  • FLGT 2016
  • GERN 1996
  • Fundamental
  • Price
  • FLGT $30.25
  • GERN $1.20
  • Analyst Decision
  • FLGT Buy
  • GERN Buy
  • Analyst Count
  • FLGT 3
  • GERN 7
  • Target Price
  • FLGT $28.33
  • GERN $3.00
  • AVG Volume (30 Days)
  • FLGT 411.7K
  • GERN 9.0M
  • Earning Date
  • FLGT 11-07-2025
  • GERN 11-05-2025
  • Dividend Yield
  • FLGT N/A
  • GERN N/A
  • EPS Growth
  • FLGT N/A
  • GERN N/A
  • EPS
  • FLGT N/A
  • GERN N/A
  • Revenue
  • FLGT $315,549,000.00
  • GERN $183,403,000.00
  • Revenue This Year
  • FLGT $15.19
  • GERN $166.20
  • Revenue Next Year
  • FLGT $10.58
  • GERN $55.83
  • P/E Ratio
  • FLGT N/A
  • GERN N/A
  • Revenue Growth
  • FLGT 13.61
  • GERN 522.13
  • 52 Week Low
  • FLGT $14.57
  • GERN $1.04
  • 52 Week High
  • FLGT $31.04
  • GERN $4.21
  • Technical
  • Relative Strength Index (RSI)
  • FLGT 71.79
  • GERN 52.29
  • Support Level
  • FLGT $28.65
  • GERN $1.05
  • Resistance Level
  • FLGT $31.04
  • GERN $1.28
  • Average True Range (ATR)
  • FLGT 1.33
  • GERN 0.07
  • MACD
  • FLGT 0.21
  • GERN 0.01
  • Stochastic Oscillator
  • FLGT 87.98
  • GERN 66.67

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: